Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Liu

Showing results (91-100 of 149) with videos related to

Pageof 15
Sort By:
Elife|December 2, 2025
<i>Eed</i> controls craniofacial osteoblast differentiation and mesenchymal proliferation from the neural crestTim Casey-Clyde, S John Liu, Angelo Pelonero, et al.
Drug Safety|February 2, 2021
Upadacitinib in Rheumatoid Arthritis: A Benefit-Risk Assessment Across a Phase III ProgramPhilip G Conaghan, Eduardo Mysler, Yoshiya Tanaka, et al.
G3 (Bethesda, Md.)|May 17, 2019
A Non-Dicer RNase III and Four Other Novel Factors Required for RNAi-Mediated Transposon Suppression in the Human Pathogenic Yeast <i>Cryptococcus neoformans</i>Jordan E Burke, Adam D Longhurst, Prashanthi Natarajan, et al.
Rheumatology (Oxford, England)|July 23, 2018
Dual inhibition of tumour necrosis factor and interleukin-17A with ABT-122: open-label long-term extension studies in rheumatoid arthritis or psoriatic arthritisMark C Genovese, Michael E Weinblatt, Philip J Mease, et al.
Clinical Rheumatology|January 30, 2023
Safety of upadacitinib in Latin American patients with rheumatoid arthritis: an integrated safety analysis of the SELECT phase 3 clinical programAdriana Maria Kakehasi, Sebastião Cezar Radominski, Marcos Daniel Baravalle, et al.
Developmental Cell|May 22, 2019
The Long Noncoding RNA Pnky Is a Trans-acting Regulator of Cortical Development In VivoRebecca E Andersen, Sung Jun Hong, Justin J Lim, et al.
Journal of the American Academy of Dermatology|May 25, 2023
Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: Results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up)Andrew Blauvelt, Barry Ladizinski, Vimal H Prajapati, et al.
Genome Biology|April 16, 2016
Single-cell analysis of long non-coding RNAs in the developing human neocortexSiyuan John Liu, Tomasz J Nowakowski, Alex A Pollen, et al.
RMD Open|October 19, 2021
Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 studyIain B McInnes, Koji Kato, Marina Magrey, et al.
The Journal of Allergy and Clinical Immunology|August 17, 2021
Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study resultsJonathan I Silverberg, Marjolein de Bruin-Weller, Thomas Bieber, et al.
Pageof 15

Showing results (91-100 of 149) with videos related to

Sort By:
Pageof 15
Elife|December 2, 2025
<i>Eed</i> controls craniofacial osteoblast differentiation and mesenchymal proliferation from the neural crestTim Casey-Clyde, S John Liu, Angelo Pelonero, et al.
Drug Safety|February 2, 2021
Upadacitinib in Rheumatoid Arthritis: A Benefit-Risk Assessment Across a Phase III ProgramPhilip G Conaghan, Eduardo Mysler, Yoshiya Tanaka, et al.
G3 (Bethesda, Md.)|May 17, 2019
A Non-Dicer RNase III and Four Other Novel Factors Required for RNAi-Mediated Transposon Suppression in the Human Pathogenic Yeast <i>Cryptococcus neoformans</i>Jordan E Burke, Adam D Longhurst, Prashanthi Natarajan, et al.
Rheumatology (Oxford, England)|July 23, 2018
Dual inhibition of tumour necrosis factor and interleukin-17A with ABT-122: open-label long-term extension studies in rheumatoid arthritis or psoriatic arthritisMark C Genovese, Michael E Weinblatt, Philip J Mease, et al.
Clinical Rheumatology|January 30, 2023
Safety of upadacitinib in Latin American patients with rheumatoid arthritis: an integrated safety analysis of the SELECT phase 3 clinical programAdriana Maria Kakehasi, Sebastião Cezar Radominski, Marcos Daniel Baravalle, et al.
Developmental Cell|May 22, 2019
The Long Noncoding RNA Pnky Is a Trans-acting Regulator of Cortical Development In VivoRebecca E Andersen, Sung Jun Hong, Justin J Lim, et al.
Journal of the American Academy of Dermatology|May 25, 2023
Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: Results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up)Andrew Blauvelt, Barry Ladizinski, Vimal H Prajapati, et al.
Genome Biology|April 16, 2016
Single-cell analysis of long non-coding RNAs in the developing human neocortexSiyuan John Liu, Tomasz J Nowakowski, Alex A Pollen, et al.
RMD Open|October 19, 2021
Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 studyIain B McInnes, Koji Kato, Marina Magrey, et al.
The Journal of Allergy and Clinical Immunology|August 17, 2021
Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study resultsJonathan I Silverberg, Marjolein de Bruin-Weller, Thomas Bieber, et al.
Pageof 15